Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

News

  • Home
  •  
  • News



  • Most Read
  • Latest Comments
  • There are no scorpions involved in this company’s latest cancer drug
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • There are no scorpions involved in this company’s latest cancer drug
    • News

    Smart pain assessment app now used by more than half of Australia’s residential aged care providers
    Public
  • There are no scorpions involved in this company’s latest cancer drug
    • News

    Fledgling fintech hopes millennials put their Douugh into micro-investing ‘super’ app
    Public
  • There are no scorpions involved in this company’s latest cancer drug
    • News

    🎵 The knee bone’s connected to the… collagen rope device (?!)
    Public
  • There are no scorpions involved in this company’s latest cancer drug
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial
    • Review
    • September 1, 2022

Latest Articles

  • Arovella completes development for cell therapy platform, moves to large scale manufacturing
    Arovella completes development for cell therapy platform, moves to large scale manufacturing
    • News

  • Chimeric Therapeutics granted US patent for its blood cancer technology
    Chimeric Therapeutics granted US patent for its blood cancer technology
    • News

  • Chimeric’s cell therapy drug moves on to Phase 1B trial to treat malignant brain cancer
    Chimeric’s cell therapy drug moves on to Phase 1B trial to treat malignant brain cancer
    • News

  • FDA grants broad orphan drug status to PTX, shoots share price up almost 30%
    FDA grants broad orphan drug status to PTX, shoots share price up almost 30%
    • News

  • Prescient Therapeutics sures supply of cell therapeutic in the hopes of commencing clinical trials
    Prescient Therapeutics sures supply of cell therapeutic in the hopes of commencing clinical trials
    • News

  • Splitit shares surge on BNPL collaboration with Mastercard
    • News

    Splitit shares surge on BNPL collaboration with Mastercard

    Payments company Splitit (ASX: SPT) is set to expedite its global growth strategy having partnered with Mastercard Inc (NYSE: MA) to develop Buy-Now-Pay-Later (BNPL) options into Mastercard’s technology suite.  Through the partnership, Splitit aims to capitalise on the global BNPL phenomenon while offering payment choices, control and simplicity to consumers and businesses.  “We are very

    Read More
    Public
  • archTIS enters Defence sector with new client for cybersecurity platform
    • News

    archTIS enters Defence sector with new client for cybersecurity platform

    Cybersecurity company archTIS (ASX: AR9) has confirmed its first entry into the lucrative Defence industry with the securing of Northrop Gruman as a major customer of their platform designed for the secure sharing of classified information. The commercial contract will see Northrop Gruman purchase 50 licenses for archTis’ Kojensi platform which will be used to

    Read More
    Public
  • Spain set to defeat Philippines in bidding war for Infigen Energy
    • News

    Spain set to defeat Philippines in bidding war for Infigen Energy

    After recommending shareholders take no action to the $1.2 billion takeover bid from UAC Energy at 80c per share, Infigen Energy (ASX: IFN) has today recommended shareholders instead accept an offer of 86c per share from Spanish energy giant Iberdrola.  The new takeover offer comes two weeks after the UAC Energy offer was made, with

    Read More
    Public
  • Wisr’s rapid loan book growth returns to pre-COVID levels
    • News

    Wisr’s rapid loan book growth returns to pre-COVID levels

    Australian credit consumers appear to be returning to financial normality based on fintech company Wisr (ASX: WZR) confirming their loan and repayment figures have returned to pre-coronavirus levels, and are rising rapidly.  The Company has reported 48% growth in their loan originations for the month of May, as Australians seek more competitive interest rates and

    Read More
    Public
  • Crowd Media secures VITAL partner for health and hygiene products across EU
    • News

    Crowd Media secures VITAL partner for health and hygiene products across EU

    Digital marketing company Crowd Media (ASX: CM8) has strengthened its online sales pipeline, partnering with VITAL Innovations for the exclusive marketing of their award-winning consumer products. This comes at a time when online business is thriving through COVID-19.   The marketing services agreement will see Crowd Media roll out safety and hygiene products from VITAL’s SuperSafe

    Read More
    Public
  • Lithium Australia’s battery storage systems approved, national rollout to come
    • News

    Lithium Australia’s battery storage systems approved, national rollout to come

    The shift towards sustainable energy solutions continues to gain momentum following regulatory approval from the Clean Energy Council for domestic power bank systems produced by Soluna, a joint venture between Lithium Australia (ASX: LIT) and DLG Energy (Shanghai) Co, to be sold in Australia.  In order to gain approval from the Clean Energy Council (CEC),

    Read More
    Public
  • Technology and I.T Lead ASX Performance by Sector through COVID-19
    • News

    Technology and I.T Lead ASX Performance by Sector through COVID-19

    Most of the Australian population in January would not have believed that in only a few months, the XJO would fall from a high of 7162 to 4402, numbers that it has not seen in over four years. While it has somewhat recovered with the index currently sitting around the 6000 mark, some indexes haveRead More
    Public
  • Top cannabis grower enters production deal with THC Global
    • News

    Top cannabis grower enters production deal with THC Global

    In preparation for legislative changes which may soon see cannabis products purchasable over the counter without a prescription, leading medicinal cannabis product manufacturer THC Global (ASX: THC) has partnered with Cannatrek to produce white-labeled CBD products at their high-volume Southport facility in Queensland.  As a sizable grower of medicinal cannabis with a diverse range of

    Read More
    Public
  • MyFiziq to partner with NuraLogix on smartphone app to screen COVID-19 symptoms
    • News

    MyFiziq to partner with NuraLogix on smartphone app to screen COVID-19 symptoms

    Health tech company MyFiziq (ASX: MYQ) has partnered with Canadian firm NuraLogix which will leverage the two company’s patented imaging technology. Using a smartphone camera, transdermal imaging and artificial intelligence (AI), the newly combined tech aims to determine a user’s probability of having COVID-19, as well as their risk of developing diseases that result in

    Read More
    Public
  • Online purchases thriving through COVID-19 as Zip revenues up 78%
    • News

    Online purchases thriving through COVID-19 as Zip revenues up 78%

    Despite COVID-19 having challenged the retail industry, consumers have substituted trips to the mall with online purchases in droves as evidenced by Zip Co’s (ASX: Z1P) results though May with the BNPL provider reporting a 78% increase in YoY monthly revenues to $15.6m. Beyond the significant increase in their online payment volumes, transaction volumes were

    Read More
    Public
  • «
  • ‹
  • 288
  • 289
  • 290
  • 291
  • 292
  • ›
  • »

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.